{"generic":"Alglucosidase Alfa","drugs":["Alglucosidase Alfa","Lumizyme","Myozyme"],"mono":{"0":{"id":"928546-s-0","title":"Generic Names","mono":"Alglucosidase Alfa"},"1":{"id":"928546-s-1","title":"Dosing and Indications","sub":[{"id":"928546-s-1-4","title":"Adult Dosing","mono":"<ul><li>Myozyme(R) and Lumizyme(TM) are manufactured by Genzyme Corporation, but at different manufacturing sites and under separate biologic license applications (BLA) .<\/li><li><b>Lysosomal alpha-1,4-glucosidase deficiency - infantile onset:<\/b> 20 mg\/kg IV over 4 hours every 2 weeks; administer infusion in a stepwise manner as tolerated<\/li><li><b>Lysosomal alpha-1,4-glucosidase deficiency - juvenile onset:<\/b> 20 mg\/kg IV over 4 hours, every 2 weeks; administer infusion in a stepwise manner as tolerated<\/li><\/ul>"},{"id":"928546-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>Myozyme(R) and Lumizyme(TM) are manufactured by Genzyme Corporation, but at different manufacturing sites and under separate biologic license applications (BLA).<\/li><li><b>Lysosomal alpha-1,4-glucosidase deficiency - infantile onset:<\/b> 20 mg\/kg IV over 4 hours every 2 weeks; administer infusion in a stepwise manner as tolerated<\/li><li><b>Lysosomal alpha-1,4-glucosidase deficiency - juvenile onset:<\/b> 20 mg\/kg IV over 4 hours, every 2 weeks; administer infusion in a stepwise manner as tolerated<\/li><\/ul>"},{"id":"928546-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>Mild to moderate hypersensitivity reaction:<\/b> Slow or temporarily stop infusion<\/li><li><b>Severe hypersensitivity reaction or anaphylaxis:<\/b> Discontinue administration and initiate medical treatment<\/li><\/ul>"},{"id":"928546-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Lysosomal alpha-1,4-glucosidase deficiency - infantile onset<\/li><li>Lysosomal alpha-1,4-glucosidase deficiency - juvenile onset<\/li><\/ul>"}]},"2":{"id":"928546-s-2","title":"Black Box Warning","mono":"<b>Intravenous (Powder for Solution)<\/b><br\/>Life-threatening anaphylactic, severe allergic, and immune-mediated reactions have been observed in patients during and after alglucosidase alfa infusion. Observe patients closely and appropriate treatment and supportive measures should be readily available. Infantile onset Pompe disease patients with compromised cardiac or respiratory function may be at risk of serious acute exacerbation due to fluid overload, and require additional monitoring.<br\/>"},"3":{"id":"928546-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928546-s-3-9","title":"Contraindications","mono":"Specific contraindications have not been determined <br\/>"},{"id":"928546-s-3-10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- Life threatening and severe anaphylaxis and allergic reactions have been reported during and up to 3 hours after infusion, with an increased risk in patients that develop IgE antibodies; monitoring recommended and discontinue use if suspected<\/li><li>-- Increased risk of serious acute cardiac or respiratory exacerbation in infantile-onset Pompe disease patients with compromised cardiac or respiratory function; monitoring recommended<\/li><li>-- Immune-mediated cutaneous reactions have occurred several weeks to 3 years after therapy initiation; monitoring recommended and discontinuation may be necessary<\/li><li>Cardiovascular:<\/li><li>-- Serious exacerbation of cardiac compromise in patients with compromised cardiac function may occur during infusions; monitoring recommended<\/li><li>-- Acute cardiorespiratory failure has been reported in infantile-onset Pompe disease patients with underlying cardiac hypertrophy<\/li><li>Immunologic:<\/li><li>-- Antibody development may occur, typically within 3 months of treatment; monitoring recommended<\/li><li>Renal:<\/li><li>-- Nephrotic syndrome secondary to membranous glomerulonephritis has been reported in Pompe patients with persistent positive anti-rhGAA IgG antibodies; monitoring recommended and consider treatment interruption<\/li><li>Respiratory:<\/li><li>-- Serious exacerbation of respiratory compromise in patients with acute underlying respiratory illness or compromised respiratory function may occur during infusions; monitoring recommended<\/li><li>Other:<\/li><li>-- Infusion reactions, some severe, may occur during and up to 3 hours after infusion; monitoring recommended; decrease rate or temporarily stop infusion; consider immediate discontinuation with severe reaction; use caution with retreatment<\/li><li>-- Increased risk of infusion reactions with higher infusion rates, advanced Pompe disease, or acute illness; monitoring recommended; decrease rate or temporarily stop infusion; consider immediate discontinuation with severe reaction; use caution with retreatment<\/li><li>-- Use caution when administering general anesthesia during placement of central venous catheter for alglucosidase alfa infusion<\/li><\/ul>"},{"id":"928546-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"928546-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"928546-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Abnormal blood pressure, Increased (5%), Chest discomfort (6.7%), Tachycardia (8% to 23%)<\/li><li><b>Dermatologic:<\/b>Flushing (13% to 21%), Hyperhidrosis (8.3%), Rash (3.3% to 18%), Urticaria (8.3% to 21%)<\/li><li><b>Gastrointestinal:<\/b>Constipation (23%), Diarrhea (3% to 62%), Vomiting (5% to 49%)<\/li><li><b>Hematologic:<\/b>Anemia (31%)<\/li><li><b>Immunologic:<\/b>Antibody development, IgG (89% to 100%)<\/li><li><b>Musculoskeletal:<\/b>Muscle twitch (6.7%)<\/li><li><b>Neurologic:<\/b>Tremor (5%)<\/li><li><b>Respiratory:<\/b>Cough (8% to 46%), Tachypnea (8% to 23%)<\/li><li><b>Other:<\/b>Complication of infusion (51%), Fever (15%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiac arrest, Sudden cardiac death, Ventricular arrhythmia<\/li><li><b>Dermatologic:<\/b>Skin necrosis<\/li><li><b>Immunologic:<\/b>Anaphylaxis (6.7%), Hypersensitivity reaction (14%)<\/li><li><b>Musculoskeletal:<\/b>Arthropathy, Severe inflammatory<\/li><li><b>Neurologic:<\/b>Seizure<\/li><li><b>Renal:<\/b>Nephrotic syndrome, Proteinuria<\/li><li><b>Respiratory:<\/b>Hypoxia (8% to 41%), Respiratory arrest, Respiratory distress (33%), Respiratory failure (31%)<\/li><li><b>Other:<\/b>Angioedema<\/li><\/ul>"},"6":{"id":"928546-s-6","title":"Drug Name Info","sub":{"0":{"id":"928546-s-6-17","title":"US Trade Names","mono":"<ul><li>Myozyme<\/li><li>Lumizyme<\/li><\/ul>"},"2":{"id":"928546-s-6-19","title":"Class","mono":"<ul><li>Enzyme<\/li><li>Enzyme Replacement<\/li><\/ul>"},"3":{"id":"928546-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"928546-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"928546-s-7","title":"Mechanism Of Action","mono":"Alglucosidase alfa provides a recombinant, exogenous source of acid alpha-glucosidase (GAA), the enzyme that is absent or deficient in Pompe disease (glycogen storage disease type II). Alglucosidase alfa binds to lysosomes and is internalized, resulting in increased enzymatic activity in cleaving glycogen.<br\/>"},"8":{"id":"928546-s-8","title":"Pharmacokinetics","sub":{"3":{"id":"928546-s-8-26","title":"Excretion","mono":"<ul><li>Total body clearance, pediatrics: 25 mL\/hr\/kg<\/li><li>Total body clearance, adults: 601 mL\/hr<\/li><\/ul>"},"4":{"id":"928546-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Pediatrics, 2.3 hours<\/li><li>Adults, 2.4 hours<\/li><\/ul>"}}},"9":{"id":"928546-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>reconstitute with 10.3 mL sterile water for injection to a concentration of 5 mg\/mL; avoid forceful impact of water on powder; do not invert, roll, or shake<\/li><li>immediately dilute reconstituted solution in normal saline to a final concentration of 0.5 to 4 mg\/mL; do not shake<\/li><li>thin white strands or translucent fibers, usually less than 10 per vial, may appear in reconstituted or diluted solutions; these are removed via inline filtration<\/li><li>administer immediately or may be stored for up to 24 hours under refrigerated conditions (2 to 8 degrees C); do not freeze and protect from light<\/li><li>administer through a 0.2-micron, low-protein-binding, inline filter<\/li><li>initiate infusion at a rate of 1 mg\/kg\/hr and increase by 2 mg\/kg\/hr every 30 minutes, if tolerated, to a maximum rate of 7 mg\/kg\/hr; total infusion time approximately 4 hours; assess vital signs every 30 minutes; slow or temporarily stop infusion for infusion reactions<\/li><\/ul>"},"10":{"id":"928546-s-10","title":"Monitoring","mono":"<ul><li>improvement in the signs and symptoms of Pompe disease is indicative of efficacy<\/li><li>IgG antibody formation; every 3 months for 2 years, and annually thereafter<\/li><li>IgG titers or IgE antibodies; in patients develop hypersensitivity reactions, other immune-mediated responses, or lose clinical response; contact Genzyme Corporation (1-800-745-4447) for information on testing and to obtain a sample collection box<\/li><li>liver enzymes; baseline and periodically<\/li><li>urinalysis; periodically<\/li><li>vital signs; each time infusion rate is stepped up (approximately every 30 minutes during infusion)<\/li><li>infusion reactions; particularly in patients with acute illness or compromised cardiac and\/or respiratory function, and in patients who develop IgE antibodies; prolonged observation may be necessary<\/li><li>systemic immune complex-mediated reactions involving skin and other organs<\/li><\/ul>"},"11":{"id":"928546-s-11","title":"How Supplied","mono":"<ul><li><b>Lumizyme<\/b><br\/>Intravenous Powder for Solution: 50 MG<br\/><\/li><li><b>Myozyme<\/b><br\/>Intravenous Powder for Solution: 50 MG<br\/><\/li><\/ul>"},"13":{"id":"928546-s-13","title":"Clinical Teaching","mono":"<ul><li>Warn patient that drug may cause hypersensitivity reactions (eg, anaphylactic shock, cardiac arrest, respiratory distress, hypotension, bradycardia, hypoxia, bronchospasm, throat tightness, dyspnea, angioedema, and urticaria) during or up to 3 hours after infusion.<\/li><li>Side effects may include rash, urticaria, flushing, fever, headache, hyperhidrosis, nausea, cough, chest discomfort, dizziness, or muscle twitch.<\/li><li>Advise patient and caregivers to report symptoms of immune-mediated reactions, which may occur several weeks to 3 years after infusion initiation.<\/li><li>Instruct patient and caregivers to report symptoms of cardiorespiratory failure.<\/li><\/ul>"}}}